Israel - English - Ministry of Health

bayer israel ltd - acetylsalicylic acid - tablets enteric coated - acetylsalicylic acid 100 mg - acetylsalicylic acid - acetylsalicylic acid - the primary prevention of coronary heart disease in patients at increased risk and the secondary prevention of thrombotic cerebrovascular or cardiovascular disease.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - epoprostenol as sodium - powder for solution for infusion - epoprostenol as sodium 1.5 mg/vial - epoprostenol - epoprostenol - flolan is indicated for the treatment of pulmonary arterial hypertension (pah) (idiopathic or heritable pah and pah associated with connective tissue diseases) in patients with who functional class iii-iv symptoms to improve exercise capacity

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - epoprostenol as sodium - powder for solution for infusion - epoprostenol as sodium 0.5 mg/vial - epoprostenol - epoprostenol - flolan is indicated for the treatment of pulmonary arterial hypertension (pah) (idiopathic or heritable pah and pah associated with connective tissue diseases) in patients with who functional class iii-iv symptoms to improve exercise capacity

Israel - English - Ministry of Health

rafa laboratories ltd - treprostinil as sodium - solution for injection - treprostinil as sodium 5 mg/ml - treprostinil - treprostinil - remodulin is indicated as a continuous subcutaneous infusion or intravenous infusion for the treatment of primary pulmonary arterial hypertension and pulmonary arterial hypertension associated with connective tissue disorders. pulmonary hypertension associated with congenital systemic to pulmonary shunts.

Israel - English - Ministry of Health

rafa laboratories ltd - treprostinil as sodium - solution for injection - treprostinil as sodium 2.5 mg/ml - treprostinil - treprostinil - remodulin is indicated as a continuous subcutaneous infusion or intravenous infusion for the treatment of primary pulmonary arterial hypertension and pulmonary arterial hypertension associated with connective tissue disorders. pulmonary hypertension associated with congenital systemic to pulmonary shunts.

Israel - English - Ministry of Health

omrix biopharmaceuticals ltd, israel - calcium chloride; protein clottable; thrombin - solution - thrombin 800 - 1200 iu / 1 ml; calcium chloride 5.6 - 6.20 mg / 1 ml; protein clottable 50 - 90 mg / 1 ml - combinations - combinations - general haemostasis : evicel is used as supportive treatment in surgery where standard surgical techniques are insufficient, for improvement of haemostasis. efficacy has been demonstrated in liver surgery and orthopaedic surgery.evicel ® is also indicated as suture support for haemostasis for suture line sealing in dura mater closure.

Israel - English - Ministry of Health

medison pharma ltd - dextromethorphan hydrobromide; quinidine sulfate - capsules - quinidine sulfate 10 mg; dextromethorphan hydrobromide 20 mg - quinidine - quinidine - for the treatment of pseudobulbar affect (pba) .

Israel - English - Ministry of Health

unipharm ltd, israel - amiodarone hydrochloride - tablets - amiodarone hydrochloride 200 mg - amiodarone - amiodarone - coronary insufficiency, arrhythmias resistant to other treatments.

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - alprostadil - concentrate for solution for infusion - alprostadil 0.5 mg/ml - alprostadil - alprostadil - for palliative therapy to maintain the patency of the ductus arteriosus.

Israel - English - Ministry of Health

unipharm ltd, israel - valsartan - tablets - valsartan 160 mg - valsartan - valsartan - for treatment of hypertension. valsartan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial valsartan significantly reduced hospitalizations for heart failure. there is no evidence that valsartan provides added benefits when it is used with an adequate dose of an ace inhibitor. valsartan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.